by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
Every launch team asks: “Who benefits if we succeed?” Patients, shareholders, and sometimes physicians all make the list. But very few ask the opposite, arguably more important, question: “Who loses if we win?” This question is powerful because every new therapy...
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
Market access is littered with myths that sound plausible — until they quietly drain millions from your launch budget. Believing them isn’t just harmless optimism; it’s expensive optimism. Let’s unpack the three most common offenders. Myth 1: Approval guarantees...
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
When people talk about “tough stakeholders” in market access, the usual suspects are regulators, HTA bodies, and payers. Challenging? Absolutely. Critical? Yes. But in practice, the single toughest stakeholder to align isn’t in Mumbai, Ankara or Manchester; it’s your...
by Tony Akiwumi | Nov 4, 2025 | Pharma / Market Access
“Patient centricity” is everywhere in pharma these days. Let’s resist the temptation to name the consultancy behind this ubiquitous and unquantifiable credo. Given the slide decks, strategy documents, and press releases, the patient appears to be the most important...
by Tony Akiwumi | Nov 1, 2025 | Pharma / Market Access
Pharma loves a good launch. They invest billions. They polish the slides meticulously. A new medicine hits the market with the same excitement as the latest iPhone. And then… silence. Most launches fail to meet expectations. Not because the science is weak. Not...
by Tony Akiwumi | Nov 1, 2025 | Pharma / Market Access
Artificial intelligence is rewriting the possibilities of healthcare. From early diagnosis to personalised treatment and operational efficiency, its potential is undeniable. Yet the greatest barrier to adoption is not technology — it is trust. Trust determines whether...
